Multiple sclerosis spasticity
Muscle stiffness and spasm in multiple sclerosis. Substantial evidence for patient-reported improvement; weaker for clinician-measured.
What the evidence says
NASEM 2017: substantial evidence for improving patient-reported MS spasticity symptoms with oral cannabinoids. Only limited evidence for clinician-measured spasticity.
NASEM drew a careful distinction here that is worth preserving. There is substantial evidence that oral cannabinoids improve patient-reported MS spasticity symptoms — how the spasticity feels to the person living with it. There is only limited evidence for improvement in clinician-measured spasticity.
That gap is not a reason to dismiss the benefit. It does mean that objective measures may not move much even when someone reports feeling considerably better.
Nabiximols (Sativex), an oromucosal THC:CBD spray, is approved for MS spasticity in the UK, Canada, and the EU. It is not FDA-approved in the United States.
What to ask for
This is a starting point, not a prescription. Take it to a licensed dispensary and ask to see the batch certificate of analysis.
- Suggested ratio
- Balanced 1:1 THC:CBD
- Starting THC dose
- 2.5 mg
- Commonly chosen profile
- Balanced hybrid
- Time of day
- either
Cannabinoids
- THC
The main intoxicating compound in cannabis. It drives most of what people mean by "high," and it is also the cannabinoid behind most documented therapeutic effects.
- CBD
Non-intoxicating. The only cannabis-derived compound with an FDA-approved medicine behind it, and the cannabinoid most often used to soften THC.
Terpenes to look for
Commonly present in products people choose for this. Terpene effect claims are preclinical — this is a way to find a product again, not a promise about how it will feel.
- Myrcene
Earthy, musky, faintly sweet
- Beta-caryophyllene
Peppery, woody, spicy
- Linalool
Floral, lavender, slightly spicy
Formats
- TinctureOnset 15–90 min · lasts 4–8 h
Liquid extract dosed by dropper. The most precise way to titrate an oral dose in small increments.
- CapsuleOnset 30–120 min · lasts 6–8 h
Swallowed softgel or capsule. Behaves like an edible with pharmacy-style consistency.
- TopicalOnset 15–60 min · lasts 2–6 h
Creams, balms, and patches applied to skin. Non-transdermal topicals do not produce intoxication.
Get a personalised starting point
Answer four questions and we will adjust the dose for your experience level and find licensed dispensaries near you.
Get guidanceTalk to a doctor if
- • You have not had an MS diagnosis confirmed
- • Spasticity is worsening rapidly
- • You take disease-modifying therapy — check interactions with your neurologist
Related conditions
- Tourette syndromeTic disorder. Limited evidence for THC capsules.
- DementiaNASEM found limited evidence that cannabinoids are INEFFECTIVE for dementia symptoms.
- Epilepsy and seizure disordersPrescription CBD has strong RCT evidence in three specific syndromes. Dispensary products do not.
- ADHDAttention-deficit/hyperactivity disorder. No supporting evidence, and acute cannabis use impairs attention.